文献速递药物相互作用

Givosiran对肝脏细胞色素P450活性影响的药物相互作用研究

A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
PubMed 文献 · Clin Pharmacol Ther · 2021-09-28

Givosiran是一种靶向肝脏ALAS1 mRNA的siRNA药物,用于治疗急性肝卟啉症。本研究采用经验证的Inje鸡尾酒法(咖啡因、氯沙坦、奥美拉唑、右美沙芬、咪达唑仑)在急性间歇性卟啉症患者中评估givosiran对5种主要CYP450酶底物药代动力学的影响,结果显示givosiran对CYP1A2和CYP2D6有中度抑制作用,对CYP3A4、CYP2C19和CYP2C9影响较弱。这是首个评估寡核苷酸治疗药物DDI的研究,提示givosiran对肝脏血红素依赖性CYP酶活性无大幅影响。

要点

  • Givosiran对CYP1A2和CYP2D6有中度抑制作用,对CYP3A4、CYP2C19和CYP2C9影响较弱。
  • Givosiran不通过CYP酶代谢,也不直接抑制或诱导CYP酶,但可能通过降低肝脏ALAS1影响血红素依赖性CYP活性。
  • 使用CYP1A2或CYP2D6底物药物时需关注givosiran的潜在中度抑制相互作用。

核心结论

  • Givosiran治疗对肝脏CYP450酶产生差异性抑制作用,对CYP1A2和CYP2D6中度抑制,对CYP3A4、CYP2C19和CYP2C9影响较弱。
  • Givosiran对肝脏血红素依赖性CYP酶活性无大幅影响。

研究设计与样本

  • 在急性间歇性卟啉症患者中使用经验证的Inje鸡尾酒评估givosiran对5种主要CYP450酶底物药代动力学的影响。
  • Inje鸡尾酒包含咖啡因(CYP1A2)、氯沙坦(CYP2C9)、奥美拉唑(CYP2C19)、右美沙芬(CYP2D6)和咪达唑仑(CYP3A4)。

主要发现

  • Givosiran对CYP1A2和CYP2D6有中度抑制作用。
  • Givosiran对CYP3A4和CYP2C19影响较小,对CYP2C9影响较弱。

临床怎么用

  • 临床使用givosiran时应关注与CYP1A2或CYP2D6底物药物的潜在相互作用。
  • Givosiran对CYP3A4、CYP2C19和CYP2C9底物药物的相互作用风险较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Givosiran (trade name GIVLAARI) is a small interfering ribonucleic acid that targets hepatic delta-aminolevulinic acid synthase 1 (ALAS1) messenger RNA for degradation through RNA interference (RNAi) that has been approved for the treatment of acute hepatic porphyria (AHP). RNAi therapeutics, such as givosiran, have a low liability for drug-drug interactions (DDIs) because they are not metabolized by cytochrome 450 (CYP) enzymes, and do not directly inhibit or induce CYP enzymes in the liver. The pharmacodynamic effect of givosiran (lowering of hepatic ALAS1, the first and rate limiting enzyme in the heme biosynthesis pathway) presents a unique scenario where givosiran could potentially impact heme-dependent activities in the liver, such as CYP enzyme activity. This study assessed the impact of givosiran on the pharmacokinetics of substrates of 5 major CYP450 enzymes in subjects with acute intermittent porphyria (AIP), the most common type of AHP, by using the validated "Inje cocktail," comprised of caffeine (CYP1A2), losartan (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and midazolam (CYP3A4). We show that givosiran treatment had a differential inhibitory effect on CYP450 enzymes in the liver, resulting in a moderate reduction in activity of CYP1A2 and CYP2D6, a minor effect on CYP3A4 and CYP2C19, and a similar weak effect on CYP2C9. To date, this is the first study evaluating the DDI for an oligonucleotide therapeutic and highlights an atypical drug interaction due to the pharmacological effect of givosiran. The results of this study suggest that givosiran does not have a large effect on heme-dependent CYP enzyme activity in the liver.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vassiliou D, Sardh E, Harper P, et al. A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Clin Pharmacol Ther. 2021. PMID: 34510420. doi:10.1002/cpt.2419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。